GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Scaled Net Operating Assets

Nicox (FRA:NXOA) Scaled Net Operating Assets : 0.68 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Nicox Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Nicox's operating assets for the quarter that ended in Jun. 2024 was €41.89 Mil. Nicox's operating liabilities for the quarter that ended in Jun. 2024 was €5.87 Mil. Nicox's Total Assets for the quarter that ended in Dec. 2023 was €52.98 Mil. Therefore, Nicox's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.68.


Nicox Scaled Net Operating Assets Historical Data

The historical data trend for Nicox's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Scaled Net Operating Assets Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.51 0.39 0.36 0.47

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.42 0.63 0.43 0.68

Competitive Comparison of Nicox's Scaled Net Operating Assets

For the Biotechnology subindustry, Nicox's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Nicox's Scaled Net Operating Assets falls into.


;
;

Nicox Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Nicox's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(41.721-6.414)/75.843
=0.47

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=52.98 - 11.259
=41.721

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=31.567 - 25.153 - 0
=6.414

Nicox's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Dec. 2023 )
=(41.894-5.87)/52.98
=0.68

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=49.549 - 7.655
=41.894

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=29.561 - 20.013 - 3.678
=5.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nicox Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Nicox's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox Business Description

Industry
Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines